As you may already checked up your self the new member of the management team, Rita Kelley, have worked with Valcade at Millenium ( bought by Takeda). Have a look at slide 5 ( see link belov)for the development of sales for Valcade. Valcade is labeled for a sister disease to AML, named multiple myeloma. There are some 14 000 patients in the Valcade target patient group. The treatment was at this time in 2 lines.
The figures are just for the US market. Do not look at the absolut figures but the surplus demand you can see filled the first two years. After that there is a linear increase. Look at the sales the first year. The drug was approved in the spring that year. More than double sales the next year.
As stated before: Welcome to our management team Rita Kelley!
For my own idea of investing in Epicept, to have benefit from the cash-flow valuation coming from the EU a n d US Ceplene sales, the graph for the first 1,5 year of sales is excellent!
It is hard to find relevant objects when you compair substances. Can you come closer than this:
The same Rita Kelley will now, again, build up the sales organisation and tactics for a leukemia drug. Ceplene this time. The price at that time was some 20 000$. Now, seven years later, the price for Ceplene is some 40 000$ per treatment.